Temisis Therapeutics

Temisis Therapeutics is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing an inflammatory component. Its main asset in dermatology is TEM1657, a small molecule that helps remit psoriasis symptoms both when administered orally or topically.